 |
 |
I remeber budipine being discussed on this list years ago. There must be something in the archives maryse > Just found this...more serious fx, though if none of these conditions > pertains, it seems to me that budipine still might be a good choice and > could add one more stop on the way to DBS. > > Kathleen > > > http://apps.who.int/medicinedocs/fr/d/Jh1466e/2.6.html#Jh1466e.2.6 > > Budipine - revised data sheet: cardiac adverse reactions > > *Germany.* The manufacturer of the antiparkinsonian agent, budipine > (Parkinsan®: Byk Gulden Lomberg and Lundbeck) has revised the product > information for this product to extend the contraindications to include > patients with cardiomyopathy, myocarditis and AV Block II and III as well > as > patients with a history of ventricular arrhythmia, especially tachycardia > (torsade de pointes). In addition an electrocardiogram should be performed > before the start of therapy, then again one to three weeks afterwards and > on > increase of the dosage. Patients with a QTc value over 420 ms or > discernible > U-waves, or with an increase in QTc of over 60 ms and accordingly a QTc > time > of over 480 ms and discernible U-waves when taking budipine are excluded > from treatment. > > As regards risk factors for electrolyte imbalance, e.g. diuretic > medication, > frequent vomiting and/or diarrhoea, use of insulin in an emergency, kidney > disease or anorexia, laboratory tests should be performed, especially for > potassium and magnesium. As soon as symptoms such as palpitations, > dizziness > or syncope appear, budipine must be withdrawn and, if necessary, the > patient > examined for QT-prolongation. > > This action was taken in the context of the ongoing review of marketed > products carried out by the Federal Institute for Drugs and Medical > Devices > which found that the incidence of cardiac adverse reactions was not > adequately reflected in the product information. > > *References: Deutsche Apotheker Zeitung 140(41): 4662 (2000).* > > > > [image: Afficher le > document]<http://apps.who.int/medicinedocs/fr/d/Jh1466e/4.1.html>Safety > of Herbal medicines - Discussion at the 23rd meeting of national drug > monitoring centres, Tunisia, November > 2000<http://apps.who.int/medicinedocs/fr/d/Jh1466e/4.1.html> [image: > Afficher le > document]<http://apps.who.int/medicinedocs/fr/d/Jh1466e/4.2.html>Effects > of paracetamol pack size restriction on > overdose<http://apps.who.int/medicinedocs/fr/d/Jh1466e/4.2.html> > > > > 2009/10/1 Kathleen Cochran <[log in to unmask]> > >> More about the "new" treatment, budipine...new in 1986, that is. Why is >> this not part of the accepted regimen for tremor dominant PD? Does the >> lower >> case "b" mean that perhaps no one makes much money from it? >> >> http://www.springerlink.com/content/q65m76n526027107/ >> >> Kathleen >> >> 2009/10/1 rayilynlee <[log in to unmask]> >> >> Rayilyn Brown >>> Director AZNPF >>> Arizona Chapter National Parkinson Foundation >>> [log in to unmask] >>> >>> >>> From: Diane Wyshak >>> Sent: Wednesday, September 30, 2009 11:31 AM >>> To: ray ; chew Nee Kong >>> Subject: Good and bad news for Tremor dominant wpd - NeuroTalk >>> Communities >>> >>> >>> >>> http://neurotalk.psychcentral.com/showthread.php?t=104263 >>> >>> ---------------------------------------------------------------------- >>> To sign-off Parkinsn send a message to: mailto: >>> [log in to unmask] >>> In the body of the message put: signoff parkinsn >>> >> >> > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn